Dr. Vivek Subbiah is the Chief, early-phase drug development across Sarah Cannon Research Institute (SCRI). The Sarah Cannon Research Institute (SCRI), is one of the world’s leading oncology research organizations conducting clinical trials. Dr. Subbiah oversees SCRI’s nine drug development units and lead the expansion of early-phase capabilities and programs across the organization's growing research network of more than 1,300 physicians at more than 250 locations in 24 states.

A transformative and experienced leader in cancer clinical trial design and implementation, Dr. Subbiah comes to SCRI from the University of Texas MD Anderson Cancer Center where he was an associate professor in the Department of Investigational Cancer Therapeutics (A Phase I Program). During his near 15-year tenure there, Dr. Subbiah held several leadership roles including executive director, Medical Oncology Research, MD Anderson Cancer Network as well as clinical medical director, Division of Cancer Medicine where he oversaw both the outpatient and inpatient clinical care delivery operations for the Phase I program. His role in leading many drugs to FDA approval including developing tumor agnostic approaches to target mutations like RET and BRAF are now benefiting countless patient populations. Dr. Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other agencies across the world. Furthermore, he has an exceptional track record of effectively bringing together multidisciplinary clinical trials teams, early career physician investigators, and physicians in training, all with the shared commitment to bringing novel therapies to patients with cancer. Having trained in both pediatric hematology & oncology as well as adult medical oncology, Dr. Subbiah is uniquely positioned to bring cutting-edge therapeutics across the age continuum from adolescent/young adults (AYAs) to older adults with cancer.

Dr. Subbiah has authored over 350 peer-reviewed publications in several high-impact journals such as The New England Journal of Medicine, Nature Medicine, Journal of Clinical Oncology, JAMA Oncology, Cancer Discovery, Lancet Oncology, Nature Reviews Clinical Oncology, Lancet Diabetes and Endocrinology, and Clinical Cancer Research. He is on the editorial board of prestigious journals and is a member of the ESMO Precision Oncology Working group. He is the recipient of two NIH R01 funding awards and has received many awards including Andrew Sabin Family fellowship for 2021-2022 and The Emil Frei III Award for Translational Research in 2021.

After finishing his medical education in India, Dr. Subbiah completed a combined residency program in Internal Medicine and Pediatrics at Case Western Reserve University, MetroHealth, Cleveland, Ohio. He received board-certifications in both Internal Medicine and Pediatrics and has completed fellowships in both Adult and Pediatric Oncology at MD Anderson.